Israel Moves to Ban Smoked Medical Cannabis, Push Extracts Only

Israel's Health Ministry has proposed eliminating smoked cannabis flower from its medical program, recommending that patients switch exclusively to extracts and precision inhalers.

The proposal marks a sharp departure from global medical cannabis norms, where flower remains the dominant format despite growing extract markets. Israel operates one of the world's most established medical cannabis programs, with approximately 130,000 registered patients—roughly 1.5% of the country's population.

"The ministry believes that smoking cannabis presents unnecessary health risks that can be avoided through alternative delivery methods," according to the proposal circulating among Israeli cannabis industry stakeholders.

The recommendation has sparked immediate pushback from patient advocacy groups and licensed producers. Critics argue that eliminating flower would restrict patient choice and potentially increase costs, as extracts and precision inhalers typically carry higher price points than dried flower.

The Medical Argument

Israeli health officials cite respiratory concerns as the primary driver behind the proposal. Combustion of plant material—whether tobacco or cannabis—produces tar and carcinogens that can damage lung tissue over time.

But the move puts Israel at odds with medical cannabis programs in Germany, Australia, and most U.S. states, where flower accounts for 60-70% of medical sales. Even countries with conservative cannabis policies, like the United Kingdom, permit prescribed cannabis flower for specific conditions.

The ministry's proposal doesn't address vaporization of flower, which heats cannabis below combustion temperatures. That omission has raised questions about whether the policy stems from health concerns or broader regulatory objectives.

Industry Impact

For Israeli cannabis producers, the stakes are substantial. The country's licensed cultivation sector has invested heavily in indoor growing facilities optimized for flower production. A shift to extracts-only would require significant capital reallocation toward processing infrastructure.

Several Israeli cannabis companies have begun expanding into international markets, positioning themselves as premium flower exporters to Germany and other European medical markets. A domestic ban on flower could complicate those export strategies, even if the policy doesn't technically affect international sales.

The proposal also arrives as Israel debates broader cannabis reforms. Lawmakers have discussed adult-use legalization for years, though no concrete legislation has advanced. A medical program restricted to extracts could create unusual policy dynamics if recreational flower sales were later permitted.

What Happens Next

The Health Ministry's recommendation now enters a public comment period, during which patient groups, medical professionals, and industry stakeholders can submit formal responses. No timeline has been announced for a final decision.

Patient advocates are organizing opposition campaigns, arguing that many users find flower more effective for their conditions than processed extracts. Some patients report better symptom control with whole-plant medicine, citing the entourage effect—though research on that phenomenon remains limited.

The proposal could also face legal challenges if implemented. Israel's medical cannabis framework was built around patient access to various formats, and restricting options might conflict with existing regulatory structures.

For now, Israeli dispensaries continue selling flower alongside extracts and other products. But if the ministry moves forward, Israel would become the first major medical cannabis market to eliminate smoked flower entirely—a development that could influence policy debates in other countries weighing similar restrictions.

---

This article is based on original reporting by mjbizdaily.com.